Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

OBJECTIVE This study assessed the incidence of serious adverse events of diabetic ketoacidosis (DKA) among patients with type 2 diabetes treated with canagliflozin. RESEARCH DESIGN AND METHODS All serious adverse events of DKA and related events (ketoacidosis, metabolic acidosis, and acidosis) from 17,596 patients from randomized studies of canagliflozin through 11 May 2015 were analyzed. RESULTS Serious adverse events of DKA and related events were reported in 12 patients (0.07%), including 4 (0.07%), 6 (0.11%), and 2 (0.03%) treated with canagliflozin 100 and 300 mg and comparator, respectively; corresponding incidence rates were 0.522, 0.763, and 0.238 per 1,000 patient-years, respectively. Most patients with DKA and related events had a blood glucose >300 mg/dL (16.7 mmol/L) at presentation of DKA, were on insulin, and had DKA-precipitating factors, including some with type 1 diabetes/latent autoimmune diabetes of adulthood. CONCLUSIONS DKA and related events occurred at a low frequency in the canagliflozin type 2 diabetes program, with an incidence consistent with limited existing observational data in the general population with type 2 diabetes.

[1]  D. Russell-Jones,et al.  SGLT inhibition and euglycaemic diabetic ketoacidosis. , 2015, The lancet. Diabetes & endocrinology.

[2]  F. Pattou,et al.  Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion , 2015, Nature Medicine.

[3]  B. Bode,et al.  Long‐term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes , 2015, Diabetes, obesity & metabolism.

[4]  Yuichiro Yamada,et al.  Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet , 2015, Journal of diabetes investigation.

[5]  K. Mahaffey,et al.  Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes , 2014, Diabetes Care.

[6]  G. Bakris,et al.  Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease , 2014, Diabetes, obesity & metabolism.

[7]  Lawrence A. Leiter,et al.  Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study , 2014, Diabetes Care.

[8]  G. Capuano,et al.  Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus☆ , 2014, Journal of clinical & translational endocrinology.

[9]  G. Meininger,et al.  Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone , 2014, Diabetes, obesity & metabolism.

[10]  R. DeFronzo,et al.  Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. , 2014, The Journal of clinical investigation.

[11]  T. Heise,et al.  Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. , 2014, The Journal of clinical investigation.

[12]  W. Cefalu,et al.  Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study , 2014, Current medical research and opinion.

[13]  G. Charpentier,et al.  Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial , 2013, International journal of clinical practice.

[14]  Lawrence A Leiter,et al.  Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial , 2013, The Lancet.

[15]  A. Januszewicz,et al.  Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial , 2013, Diabetologia.

[16]  J. Rosenstock,et al.  Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea , 2013, Diabetes Care.

[17]  K. Mahaffey,et al.  Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. , 2013, American heart journal.

[18]  B. Bode,et al.  Efficacy and Safety of Canagliflozin Treatment in Older Subjects With Type 2 Diabetes Mellitus: A Randomized Trial , 2013, Hospital practice.

[19]  G. Bakris,et al.  Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease , 2013, Diabetes, obesity & metabolism.

[20]  K. Kim,et al.  Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise , 2013, Diabetes, obesity & metabolism.

[21]  J. Eriksson,et al.  Ketoacidosis occurs in both Type 1 and Type 2 diabetes— a population‐based study from Northern Sweden , 2008, Diabetic medicine : a journal of the British Diabetic Association.